Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02721420
Other study ID # P.02/15/1679
Secondary ID
Status Recruiting
Phase Phase 3
First received February 13, 2016
Last updated January 30, 2018
Start date March 24, 2016
Est. completion date December 2019

Study information

Verified date January 2018
Source University of Malawi College of Medicine
Contact Kamija Phiri, PhD
Phone +265999957048
Email kphiri@medcol.mw
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background and rationale: Children hospitalised with severe anaemia in Africa are at high risk of readmission or death within 6 months after discharge. No strategy specifically addresses this post-discharge period. In Malawi, 3 months of post-discharge malaria chemoprevention (PMC) with monthly 3-day treatment courses of artemether-lumefantrine (AL) in children with severe malarial anaemia prevented 31% of deaths and readmissions. The effect was in addition to the effect of insecticide-treated bednets. There is now need to design and evaluate effective delivery mechanism for PMC within the health system.


Description:

Objectives: The primary objective of the trial is to determine the optimum PMC delivery mechanism by comparing community- versus health facility-based strategies in order to inform policy.

Study Type: This is a single-centre, matched, cluster randomized, 5-arm, factorial design trial comparing the uptake of PMC-DHP delivered through health facility or community-based approaches with or without SMS/HSA reminders.

Site: 90 villages in the catchment areas of Zomba Central hospital in southern Malawi

Study Population:

Inclusion criteria: convalescent children aged less than 5 years and weighing >5 kg admitted with severe anaemia (haemoglobin<5g/dL / Ht<15%); clinically stable, able to take or switch to oral medication; post-transfusion Hb >5g/dL.

Exclusion criteria: blood loss due to trauma, malignancy, known bleeding disorders or sickle cell trait, known hypersensitivity to study drug, known heart conditions, non-resident in study area, previous participation in study, known need at enrolment for prohibited medication and scheduled surgery during the course of the study. HIV infection and cotrimoxazole prophylaxis are not exclusion criteria

Study Interventions:

All children will receive Dihydroartemisinin-piperaquine (3-day treatment courses, given 2,6 and 10 weeks after discharge) either:

1. at discharge + SMS Reminder;

2. at discharge + No SMS Reminder;

3. at discharge + HSA Reminder;

4. at OPD + SMS Reminder; or

5. at OPD + No SMS Reminder

Outcome Measures:

Primary: 100% of PMC drugs uptake (defined as administration of all 3-day treatment courses, given 2, 6 and 10 weeks after discharge) assessed by unannounced spot checks.

Follow-up procedures: Children will be followed up for 15 weeks by passive case detection in 2 phases: Pre-PMC (2 weeks between hospital admission and 2 weeks post-discharge); PMC (2-14 weeks post-discharge)

Sample Size: A sample size of 75 children per arm (375 total children) allows for a detection of 25% increase in uptake from 50% to 75% with 10% loss to follow-up (power 90%, α=0.05).

Data Analysis: The % of children receiving IPTpd according to schedule will be compared by relative risks (95% CI), adjusted for prognostic factors at baseline using log binomial or Poisson regression with adjustment for cluster effects


Recruitment information / eligibility

Status Recruiting
Enrollment 375
Est. completion date December 2019
Est. primary completion date March 2019
Accepts healthy volunteers No
Gender All
Age group 4 Months to 59 Months
Eligibility Inclusion Criteria:

1. Haemoglobin <5.0g/dl or PCV <15%, or requirement for blood transfusion for other clinical reasons on or during admission to the hospital

2. Age between 4 months (inclusive) and 59 months (inclusive)

3. Body weight >5kgs

Screening (in-hospital):

1. Fulfilled the pre-study screening eligibility criteria

2. Clinically stable, able to switch to oral medication

3. Subject completed blood transfusion(s) in accordance with routine hospital practice

4. Able to feed (for breastfed children) or eat (for older children)

5. Absence of known cardiac problems

6. Provision of informed consent by parent or guardian

Randomization (at discharge):

1. Fulfilled screening eligibility criteria

2. Still clinically stable, able to take oral medication, able to feed (for breastfed children) or eat (for older children) and able to sit unaided (for older children who were able to do so prior to hospitalization

Exclusion Criteria:

1. Recognised specific other cause of severe anaemia (e.g. trauma, haematological malignancy, known bleeding disorder)

2. Known sickle cell

3. Child will reside for more than 25% of the 3.5months study period (i.e. 3 weeks or more) outside of catchment area Enrolment in the study (t=0) at discharge

4. Previous enrolment in the present study

5. Known hypersensitivity to study drug

6. Sickle cell disease

7. Known need at the time of enrolment for concomitant prohibited medication during the 14 weeks PMC treatment period.

8. On-going or planned participation into another clinical trial involving on-going or scheduled treatment with medicinal products during the course of the study (3.5 months from enrolment)

9. Known need, or scheduled surgery during the course of the study (3.5 months)

10. Suspected non-compliance with the follow-up schedule

11. Known heart conditions, or family history of congenital prolongation of the QTc interval

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
dihydroartemisinin-piperaquine

Other:
message(SMS) reminder

Health worker reminder
Health surveillance assistants reminders prior to each treatment course
short message(SMS) reminder


Locations

Country Name City State
Malawi College Of Medicine,Training and Research Unit Of Excellence,Zomba Central Hospital Zomba

Sponsors (12)

Lead Sponsor Collaborator
University of Malawi College of Medicine Imperial College London, Kenya Medical Research Institute, Liverpool School of Tropical Medicine, London School of Hygiene and Tropical Medicine, Makerere University, Ministry of Health and Population, Malawi, Ministry of Health, Malawi, The Research Council of Norway, University of Amsterdam, University of Bergen, University of Minnesota, MN

Country where clinical trial is conducted

Malawi, 

Outcome

Type Measure Description Time frame Safety issue
Other All-causes of deaths and all-causes of hospital re-admissions during the 15 week trial period. Assessment of all children who die or are hospitalised during the trial period 15 weeks
Other Assessment of the added costs of the interventions to the health system and the individual patients by conducting interviews during the 15 week trial period. 15 weeks
Other Assessment of how the study interventions are acceptable by patients and health workers by conducting focus group discussions and using self administered questionnaires during the 15 week trial period. 15 weeks
Primary Proportion of those with 100 % uptake of PMC drugs during the 15 weeks of the study period. 100 % uptake is defined as administration of all study drugs and compliance to study visits during the course of 15 weeks. 15 weeks
Secondary Proportion of those with 60% uptake of PMC drugs during the 15 weeks of the study period. 60 % uptake is defined as administration of 6 or more [but less than 9] of the daily dosages out of the total of 9 during the 15 week study period. 15 weeks
Secondary Proportion of those with 30 % uptake of PMC drugs during the 15 week trial period. 30 % PMC uptake is defined as administration of 3 or more [but less than 6] of the daily dosages out of the total of 9 during the 15 week trial period. 15 weeks
Secondary Proportion of those with <30% uptake of PMC drugs during the 15 week trial period. <30 % PMC uptake is defined as administration of less than 3 of the daily dosages out of the total of 9 assessed during the 15 week trial period. 15 weeks
See also
  Status Clinical Trial Phase
Completed NCT04601714 - Baseline Cohort Malaria Morbidity Study
Withdrawn NCT04020653 - A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria Phase 2
Terminated NCT04368910 - Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria Phase 3
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02544048 - Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Active, not recruiting NCT04704674 - Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
Completed NCT03276962 - Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age Phase 2
Completed NCT04966871 - Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults Phase 1
Completed NCT00289185 - Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants Phase 2
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Active, not recruiting NCT06153862 - Africa Ready Malaria Screening N/A
Completed NCT04545905 - Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
Recruiting NCT06278181 - Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
Withdrawn NCT02793388 - A Trial on Supervised Primaquine Use in Ethiopia Phase 4
Completed NCT02793622 - Prevention of Malaria in HIV-uninfected Pregnant Women and Infants Phase 3
Completed NCT02909712 - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania Phase 2
Withdrawn NCT02793414 - Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
Completed NCT02527005 - A Comparative Study of Azithromycin and S-P as Prophylaxis in Pregnant HIV+ Patients Phase 1